Drugs / Recombinant Human Interleukin-2
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06584006 | Sep 2024 → Nov 2027 expected | hematopoietic and lymphoid cell neoplasm, lymphopenia | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT04023149 | Apr 2020 → Jun 2021 | pemphigus vulgaris | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT00045864 | — | non-Hodgkin lymphoma | Chiron Corporation | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04893980 | Jun 2021 → Jun 2022 | chronic idiopathic urticaria | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00045877 | — | non-Hodgkin lymphoma | Chiron Corporation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05438667 Background | Jun 2023 → Jun 2028 expected | malignant pancreatic neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02876510 Background | Jun 2017 → Sep 2021 | cancer | Immatics US, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02662348 Background | Feb 2016 → Nov 2017 | esophageal cancer, gallbladder cancer, gastric cancer, intestinal cancer +2 | Yi Miao | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05207722 Background | Apr 2022 → Feb 2024 | gastroesophageal junction adenocarcinoma | Celularity Incorporated | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04131231 Comparator | Oct 2019 → Jan 2021 | breast cancer, lung cancer, pleural neoplasm | Peking Union Medical College | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human interleukin-2 | “recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection)” NCT05438667 ↗ |
| Known as | rhIL-2 | “Recombinant human interleukin-2 (rhIL-2)” NCT04893980 ↗2“recombinant human interleukin-2 (rhIL-2)” NCT04023149 ↗ “recombinant human interleukin-2(rhIL-2)” NCT04131231 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-2” NCT00045864 ↗ |
| Route | Subcutaneous | “Patients also receive low-dose Interleukin subcutaneously (SC) daily beginning 3 days before the first HER2Bi armed T cells infusion.” NCT02662348 ↗ |